11:08 AM EST, 01/16/2025 (MT Newswires) -- Femasys ( FEMY ) said Thursday that the US Patent and Trademark Office has granted a notice of allowance for an application covering the use of FemaSeed for female infertility treatment.

The company said it expects the patent to last until at least 2044.

Femasys ( FEMY ) added that it plans to file more patent applications to protect FemaSeed, FemBloc permanent birth control, and other diagnostic products, such as FemVue, FemCath, and FemCerv.

Shares of Femasys ( FEMY ) rose past 4% in recent trading activity.

Price: 1.11, Change: +0.05, Percent Change: +4.72